Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma

Inclusion Criteria

• •1. Men and women ≥ 18 years of age.
• •2. Patients must have histologic confirmation of Follicular Lymphoma (FL) (grade 1, 2 and 3A). Note: Participants who have received previous CD19-directed therapy must have a biopsy which shows CD19 expression after completion of the CD19-directed therapy.
• •3. Patients with relapsed or refractory FL previously treated with ≥1 line of systemic therapy having ≥ 1 Groupe d'Etude des Lymphomes (GELF) criteria for therapy, or Progression of Diseases within 24 months (POD24), or second relapse.
• •4. Baseline FDG-PET/CT scans must demonstrate positive lesions compatible with CT defined anatomical tumor sites. Patients should have at least one measurable site of disease per Lugano classification.
• •5. Patient should have ≥ 1 Groupe d'Etude des Lymphomes (GELF) criteria for treatment initiation).
• •* Involvement of ≥3 nodal sites, each with diameter of ≥3 cm
• •* Any nodal or extranodal tumor mass with a diameter of ≥7 cm
• •* B symptoms (fever ≥ 38 degrees Celsius of unclear etiology, night sweats, weight loss \> 10% within the prior 6 months).
• •* Risk of local compressive symptoms that may result in organ compromise
• •* Splenomegaly or splenic lesion without splenomegaly
• •* Leukopenia (leukocytes \< 1000/mm3)
• •* Leukemia (\> 5.000 lymphoma cells/mm3)
• •* Bone lesions detected on FDG-PET/CT; or
• •6. Progression or relapse within 24 months of frontline treatment in patients previously treated with ≥1 line of systemic therapy; or
• •7. Second FL relapse/progression after ≥1 line of systemic therapy. These patients will be eligible independently of GELF criteria and POD24.
• •8. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
• •9. Life expectancy of greater than 6 weeks.
• •10. Patients must have normal organ and marrow function as defined below,
• •* Absolute neutrophil count ≥1000/mm3 (unless due to lymphoma involvement of the bone marrow or spleen).
• •* Platelets ≥100,000/mm3 or ≥ 60,000/mm3 in case of bone marrow involvement by lymphoma.
• •* Hemoglobin ≥ 10 g/dL or ≥8 g/dL in case of bone marrow involvement by lymphoma.
• •* Total bilirubin \< 1.5 x within normal institutional limits (unless due to lymphoma involvement of liver or a known history of Gilbert's disease).
• •* Gamma-Glutamyl Transpeptidase (GGT)/Aspartate Aminotransferase (AST)/(SGOT)/Alanine Aminotransferase (ALT)(SGPT) ≤ 2.5 × institutional upper limit of normal.
• •* Creatinine within normal institutional limits, or creatinine clearance ≥30 ml/min/1.7m\^2 for patients with creatinine levels above institutional normal (unless due to lymphoma).
• •10. History of Human immunodeficiency virus (HIV) infection. Note: HIV screening test is optional
• •11. Patients with impaired decision-making capacity.